Cargando…

Human endogenous retroviruses and cancer

Human endogenous retroviruses (HERVs) are retroviruses that infected human genome millions of years ago and have persisted throughout human evolution. About 8% of our genome is composed of HERVs, most of which are nonfunctional because of epigenetic control or deactivating mutations. However, a corr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalez-Cao, María, Iduma, Paola, Karachaliou, Niki, Santarpia, Mariacarmela, Blanco, Julià, Rosell, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	the Editorial Committee of Cancer Biology & Medicine 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250606/ https://www.ncbi.nlm.nih.gov/pubmed/28154780 http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0080

Ejemplares similares

Activation of viral defense signaling in cancer
por: Gonzalez-Cao, Maria, et al.
Publicado: (2018)

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
por: Karachaliou, Niki, et al.
Publicado: (2015)

Advances in immunotherapy for treatment of lung cancer
por: Bustamante Alvarez, Jean G., et al.
Publicado: (2015)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Tumor immune microenvironment characterization and response to anti-PD-1 therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2015)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
por: Lazzari, Chiara, et al.
Publicado: (2018)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
por: Santarpia, Mariacarmela, et al.
Publicado: (2020)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou, Niki, et al.
Publicado: (2014)

Assays for predicting and monitoring responses to lung cancer immunotherapy
por: Teixidó, Cristina, et al.
Publicado: (2015)

Human-Specific Endogenous Retroviruses
por: Buzdin, Anton
Publicado: (2007)

Human Endogenous Retrovirus Reactivation: Implications for Cancer Immunotherapy
por: Petrizzo, Annacarmen, et al.
Publicado: (2021)

Human Endogenous Retroviruses (HERVs): Shaping the Innate Immune Response in Cancers
por: Alcazer, Vincent, et al.
Publicado: (2020)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014)

Human Endogenous Retroviruses in Neurological Diseases
por: Küry, Patrick, et al.
Publicado: (2018)

The decline of human endogenous retroviruses: extinction and survival
por: Magiorkinis, Gkikas, et al.
Publicado: (2015)

Human endogenous retroviruses in cancer: Expression, regulation and function
por: Gao, Yuan, et al.
Publicado: (2021)

The discovery of endogenous retroviruses
por: Weiss, Robin A
Publicado: (2006)

Human endogenous retroviruses in development and disease
por: Mao, Jian, et al.
Publicado: (2021)

Endogenous retroviruses in the origins and treatment of cancer
por: Jansz, Natasha, et al.
Publicado: (2021)

Evaluation of Biomarkers for HER3-targeted Therapies in Cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response
por: Gonzalez-Cao, Maria, et al.
Publicado: (2016)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges
por: Karachaliou, Niki, et al.
Publicado: (2018)

Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2018)

Expressional activation and functional roles of human endogenous retroviruses in cancers
por: Zhang, Mengwen, et al.
Publicado: (2019)

Human endogenous retroviruses in cancer: Oncogenesis mechanisms and clinical implications
por: Kitsou, Konstantina, et al.
Publicado: (2022)

Endogenous Retroviruses and Human Evolution
por: Khodosevich, Konstantin, et al.
Publicado: (2002)

Immunity to human endogenous retroviruses
por: Nixon, Douglas F
Publicado: (2011)

Paleovirology of human endogenous retroviruses
por: Gifford, Robert J, et al.
Publicado: (2009)

Human endogenous retroviruses and ageing
por: Hurme, Mikko, et al.
Publicado: (2021)

Genomic flexibility of human endogenous retrovirus type K
por: Dube, Derek, et al.
Publicado: (2013)

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy
por: Teixidó, Cristina, et al.
Publicado: (2015)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
por: Karachaliou, Niki, et al.
Publicado: (2018)

Human Endogenous Retrovirus as Therapeutic Targets in Neurologic Disease
por: Giménez-Orenga, Karen, et al.
Publicado: (2021)

Transcriptional Regulation of Endogenous Retroviruses and Their Misregulation in Human Diseases
por: Zhang, Qian, et al.
Publicado: (2022)

Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
por: Santarpia, Mariacarmela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c51nknbkijqul3juk4pacd6rqd